Cadila Helthcare is planning to enter biotech business they will form separate business unit under the companies key division. The biotech division will account for 30% of cadila’s turnover. The company has alredy already filled 7 ANDAs which contains essential data submitted to US FDA for review and approval generic drugs in US.